# A lipid-induced RNA-binding protein in atherosclerosis

> **NIH NIH R01** · CEDARS-SINAI MEDICAL CENTER · 2021 · $468,031

## Abstract

PROJECT ABSTRACT
Atherosclerosis is a chronic inflammatory vascular disease resulting from maladaptive inflammatory response
to an imbalanced lipid metabolism. The cholesterol-laden, foamy macrophages found in plaques play a pivotal
role in perpetuating the sterile inflammation that is characteristic of atherosclerosis. Transcriptional control
plays a critical role in setting into motion this sterile inflammation. Post-transcriptional mechanisms that operate
in atherosclerosis can contribute to resolution of inflammation and promote plaque regression, presenting a
therapeutic opportunity. Ribonucleic acid RNA-binding proteins (RBP) alter cytokine and chemokine
messenger RNA (mRNA) stability or translation to fine-tune or turn-off the inflammatory response. RBPs also
post-transcriptionally regulate key proteins for cholesterol homeostasis and lipid metabolism in macrophages
and liver. Despite regulating inflammation, lipid metabolism and cholesterol homeostasis, thereby representing
a novel therapeutic opportunity in cardiovascular disease, only a few RBPs and their RNA targets have been
directly investigated in atherosclerosis. We made the striking discovery that Fragile X Mental Retardation
Protein (FMRP), a widely studied RBP in autism spectrum disorder, is induced by lipids in macrophages and in
mouse and human atherosclerotic plaques. We found FMRP associates with and is phosphorylated by the
Inositol-Requiring Enzyme-1 (IRE1), a conserved endoplasmic reticulum (ER) stress-sensing
kinase/endoribonuclease. ER stress and subsequent IRE1 activation in plaques is causally associated with
atherosclerosis. Enhanced IRE1 to FMRP signaling in macrophages may thus promote atherogenesis and
represent a novel therapeutic opportunity in atherosclerosis. Our preliminary work shows FMRP inhibition
leads to post-transcriptional induction of cholesterol exporters and reduces foam cell formation. Lower
cholesterol levels were reported in both FMRP-deficient mice and Fragile X patients, suggesting cholesterol
homeostasis is an important target for FMRP. Building on the insight gained through our robust preliminary
studies and incorporating additional evidence from literature, we hypothesize that post-transcriptional
suppression of cholesterol exporters by the IRE1-phosphorylated FMRP promotes macrophage foam cell
formation and atherosclerosis progression. We propose to demonstrate FMRP's role in reverse cholesterol
transport, foam cell formation and atherosclerosis in vivo. We will also investigate the consequences of
inhibiting IRE1 kinase-mediated FMRP phosphorylation on reverse cholesterol transport, foam cell formation
and atherosclerosis in mice. The completion of the proposed studies will illuminate the mechanism of action for
this novel IRE1 kinase substrate. The new knowledge gained through these studies could pave the way for the
development of effective strategies to prevent atherosclerosis by fine-tuning the homeostatic ER stress
response that is pa...

## Key facts

- **NIH application ID:** 10136084
- **Project number:** 5R01HL152156-02
- **Recipient organization:** CEDARS-SINAI MEDICAL CENTER
- **Principal Investigator:** Paul C. Dimayuga
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $468,031
- **Award type:** 5
- **Project period:** 2020-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10136084

## Citation

> US National Institutes of Health, RePORTER application 10136084, A lipid-induced RNA-binding protein in atherosclerosis (5R01HL152156-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10136084. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
